|
|
|
|
|
Coming Soon at the ASCO 2025 Annual Meeting |
|
|
|
|
| New Novartis Data at ASCO and EHA Showcase Momentum of Pioneering Portfolio with Promising Pipeline
|
| PRESS RELEASE
|
| At ASCO 2025, Novartis is presenting data from 60 abstracts across its oncology and hematology pipeline, showcasing key updates on Kisqali in younger breast cancer patients, earlier use of Pluvicto and Scemblix, and expanded Fabhalta data in PNH. Promising results from ianalumab in immune thrombocytopenia and longer-term pelabresib data in myelofibrosis further highlight the breadth of Novartis’ pipeline.
|
|
|
|
|
|
| Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025 |
| PRESS RELEASE |
| At ASCO 2025, Merck will present data across over 25 cancer types, spotlighting novel therapies such as MK-1084 (KRAS G12C inhibitor), zilovertamab vedotin, and sacituzumab tirumotecan, emphasizing its expanding antibody-drug conjugate (ADC) pipeline. Key updates also include longer-term and combination data for KEYTRUDA and WELIREG across earlier-stage cancers and multiple tumor types, reinforcing Merck’s commitment to advancing treatment innovation and addressing unmet needs in oncology.
|
|
|
|
|
|
| Phase III ARANOTE Post-Hoc Analyses Presented on HRQoL and Pain Outcomes in Patients with mCSPC Receiving NUBEQA® (Darolutamide) plus ADT
|
| PRESS RELEASE
|
| Bayer has submitted a supplemental New Drug Application to the U.S. FDA seeking to expand the indication of NUBEQA® (darolutamide) for use in combination with androgen deprivation therapy (ADT) in patients with mHSPC.
|
|
|
|
|
|
| Bicycle Therapeutics to Present Data in Locally Advanced or Metastatic Urothelial Cancer at ASCO 2025 |
| PRESS RELEASE
|
| Bicycle Therapeutics announced two poster presentations at the 2025 ASCO Annual Meeting, featuring preliminary results from the Phase 1/2 Duravelo-1 study evaluating the Nectin-4-targeting Bicycle® Drug Conjugate BT8009 in combination with pembrolizumab for patients with urothelial cancer. Additionally, they presented data from a Phase 2/3 study of BT8009 as monotherapy in locally advanced or metastatic urothelial cancer, underscoring the potential of their proprietary bicyclic peptide technology in oncology . |
|
|
|
|
|
|
|
| State of the Science: Advancing Frontiers—Novel Diagnostics and Therapeutics in Renal Cell Carcinoma and Urothelial Carcinoma - 08:00-09:15 CST |
|
|
|
|
Functional Imaging in Renal Cell Carcinoma: Enhancing Diagnosis and Treatment Strategies
Presented By: Michael Hofman, MBBS, FRACP
|
|
|
|
|
Targeting HIF2α: A New Frontier in Renal Cell Cancer Therapy
Presented By: Rana R. McKay, MD, FASC
|
|
|
|
|
Antibody-Drug Conjugates in Urothelial Carcinoma: Bridging Innovation and Community Practice
Presented By: Elizabeth Marie Wulff-Burchfield, MD
|
|
|
|
|
| Rapid Oral Abstract Session: Genitourinary Cancer—Kidney and Bladder - 13:15-14:45 CST |
|
|
|
|
Five-Year Follow-up Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab for the Treatment of Clear Cell Renal Cell Carcinoma (ccRCC)
Presented By: Naomi Balzer Haas, MD
Ipilimumab and Nivolumab in Patients with mccRCC Treated on the Phase 3 PDIGREE (Alliance A031704) Trial: Results from Step 1 Analysis
Presented By: Tian Zhang, MD, MHS
Sasanlimab in Combination with BCG in BCG-Naive, High-Risk NMIBC: Event-Free Survival (EFS) Subgroup Analyses Based on Disease Stage from the CREST Study
Presented By: Thomas Powles, MD, PhD, FCR
|
|
|
|
|
|
|
|
|
|
CLONEVO: Preoperative Abemaciclib for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC) with Molecular Response Assessment
Presented By: Bishoy Morris Faltas, MD
|
|
|
|
|
First Results of SURE-02: A Phase 2 Study of Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab (Pembro), Followed by Response-Adapted Bladder Sparing and Adjuvant Pembro, in Patients with Muscle-Invasive Bladder Cancer (MIBC)
Presented By: Andrea Necchi, MD
|
|
|
|
|
Navigating the Crossroads: Evolving Paradigms in Perioperative Management of Muscle-Invasive Bladder Cancer
Presented By: Anne Schuckman, MD, FACS
|
|
|
|
|
|
|
| Oral Abstract Session: Genitourinary Cancer—Kidney and Bladder - 09:45-12:45 CST
|
|
|
|
|
Avelumab + Sacituzumab Govitecan vs Avelumab Monotherapy as First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma: Interim Analysis from the JAVELIN Bladder Medley Phase 2 Trial
Presented By: Jeannie Hoffman-Censits, MD
|
|
|
|
|
Discussion: Breaking the Platinum Ceiling in Advanced Bladder Cancer
Presented By: Jacqueline T. Brown, MD
|
|
|
|
|
Circulating Tumor DNA (ctDNA) in Patients with Muscle-Invasive Bladder Cancer (MIBC) Who Received Perioperative Durvalumab in NIAGARA
Presented By: Thomas Powles, MD, PhD, FCRP
|
|
|
|
|
| Rapid Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile - 16:30-18:00 CST
|
|
|
|
|
Docetaxel with Androgen Deprivation Therapy and Radiotherapy for High-Risk Localized Prostate Cancer: An ICECaP Individual Patient-Data Meta-Analysis of Randomized Controlled Trials
Presented By: Praful Ravi, MBBChir, MRCP
|
|
|
|
|
|
|
| Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile - 09:00-12:00 CST
|
|
|
|
|
Use of GIP and GLP-1 Receptor Agonists in Prostate Cancer Patients
Presented By: Amy Shaver, PhD, PharmD, MPH
|
|
|
|
|
Dedicated Resources for Veteran Clinical Trial Participation: The Prostate Cancer Analysis for Therapy Choice (PATCH) Program
Presented By: Julie N. Graff, MD
Cardiovascular Event Risk in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate in the United States
Presented By: Alan Haruo Bryce, MD
‘One Button Push’ Fully Automated PSMA PET Quantification: Correlation with Progression Free and Overall Survival in Patients Undergoing [177Lu] Lu PSMA Therapy for Metastatic Castrate Resistant Prostate Cancer
Presented By: Louise Emmett, MD, FRACP, MBChB
|
|
|
|
|
|
8-Year Outcomes of Enzalutamide Versus a Non-Steroidal Anti-Androgen for Metastatic, Hormone-Sensitive Prostate Cancer (ENZAMET; ANZUP 1304)
Presented By: Alison Yan Zhang, PhD, FRACP, MBBS, MMed
|
|
|
|
|
How Low Do You Need to Go? Association Between Various Prostate-Specific Antigen Response Measures and Clinical Outcomes in Metastatic Castration‑sensitive Prostate Cancer in the Veteran Health Administration Data
Presented By: Stephen Freedland, MD
|
|
|
|
|
Secondary Outcomes by Prior Definitive Treatment (Tx) in Patients (Pts) with High-Risk Biochemically Recurrent Prostate Cancer (hrBCR) Treated with Enzalutamide (Enza) Monotherapy (Mono): EMBARK Post Hoc Analysis
Presented By: Stephen Freedland, MD
|
|
|
|
|
Neoadjuvant Niraparib in Men with DNA Repair Gene Deficient Clinically Localized Prostate Cancer: Clinical and Molecular Results from a Phase 2 Investigator-Initiated Trial
Presented By: Marc Dall'Era, MD
|
|
|
|
|
Mevrometostat in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Abiraterone Acetate: The Phase 3, Randomized MEVPRO-1 Study
Presented By: Neeraj Agarwal, MD, FASCO
|
|
|
|
|
Mevrometostat in Combination with Enzalutamide for Androgen Receptor Pathway Inhibitor (ARPI)-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): The Phase 3, Randomized MEVPRO-2 Study
Presented By: Neal D. Shore, MD, FACS
|
|
|
|
|
Mevrometostat in Combination with Enzalutamide for Androgen Receptor Pathway Inhibitor (ARPI)-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): The Phase 3, Randomized MEVPRO-2 Study
Presented By: Neal D. Shore, MD, FACS
|
|
|
|
|
| Poster Session: Genitourinary Cancer—Kidney and Bladder - 09:00-12:00 CST
|
|
|
|
|
PSMA-Delay Castration (DC): An Open-Label, Multicenter, Randomized Phase 3 Study of [177Lu]Lu-PSMA-617 Versus Observation in Patients with Metachronous PSMA-Positive Oligometastatic Prostate Cancer (OMPC)
Presented By: Alton Oliver Sartor, MD
|
|
|
|
|
Real-World Quality of Life (QOL) for Patients (Pts) with Metastatic Renal Cell Carcinoma (mRCC) Treated with Systemic Therapy (ST) in the Prospective Observational ODYSSEY Study
Presented By: Benjamin L. Maughan, MD, PharmD
|
|
|
|
|
Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer on Response to Treatment with UGN-102: A Substudy of the Phase 3 ENVISION Trial
Presented By: John Sfakianos, MD
|
|
|
|
|
Duration of Response (DoR) Following Treatment with UGN-102 in Patients with Recurrent, Low-Grade, Intermediate-Risk, Non-Muscle Invasive, Bladder Cancer: 18-Month DoR Data from the Phase 3 ENVISION Trial
Presented By: Sandip M. Prasad, MD
|
|
|
|
|
Sasanlimab in Combination with BCG in BCG-Naive in BCG-Naive, High-Risk Non–muscle-Invasive Bladder Cancer (NMIBC): Patient-Reported Outcomes from CREST
Presented By: Jens Bedke, MD
Intravesical Sacituzumab Tirumotecan in Participants with Intermediate-Risk Non–muscle-Invasive Bladder Cancer: The Phase 1/2 TroFuse-027 Study
Presented By: Joshua Meeks, MD, PhD
The uTRACT Registry: A Single-Arm, Multicenter, Prospective, and Retrospective Registry Study to Evaluate the Real-World Use of UGN-101 in Participants with Upper Tract Urothelial Carcinoma (UTUC) in the United States
Presented By: Katie Murray, DO, MS, FACS
|
|
|
|
|
|
ABLE-22: Safety and Efficacy Evaluation of Nadofaragene Firadenovec Alone or in Combination with Chemotherapy or immunotherapy—A Randomized, Open-Label, Phase 2 Study
Presented By: Siamak Daneshmand, MD
|
|
|
|
|
Predictive and Prognostic Value of Baseline PSMA-PET Total Tumor Volume and SUV Mean Within ENZA-P, a Randomized Phase II Trial of Enzalutamide Versus Enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)
Presented By: Louise Emmett, MD, FRACP, MBChB
|
|
|
|
|
|
|
| Oral Abstract Session: Genitourinary Cancer—Prostate, Testicular, and Penile - 09:45-12:45 CST
|
|
|
|
|
Health-Related Quality of Life (HRQoL) Outcomes with Darolutamide in the Phase 3 ARANOTE Trial
Presented By: Alicia K. Morgans, MD, MPH, FASCO
|
|
|
|
|
ARCHES: 5-Year Follow-up Overall Survival Analysis of Enzalutamide plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Andrew Armstrong, MD, MS
|
|
|
|
|
Phase 3 AMPLITUDE Trial: Niraparib (NIRA) and Abiraterone Acetate plus Prednisone (AAP) for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Patients (Pts) with Alterations in Homologous Recombination Repair (HRR) Genes
Presented By: Gerhardt Attard, MD, PhD
|
|
|
|
|
A Multicenter, Randomized, Phase 2, Investigator-Initiated ETCTN Trial of Olaparib + Radium-223 vs. Radium-223 in Men with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases (COMRADE): Initial Efficacy and Biomarker Analysis
Presented By: Rana R. McKay, MD, FASCO
|
|
|
|
|
C3NIRA: Randomized Phase II Study of Carboplatin-Cabazitaxel-Cetrelimab (Anti-PD-1) Induction Followed by Niraparib +/- Cetrelimab Maintenance in Men with Aggressive Variant Prostate Cancers (AVPC)
Presented By: Ana Aparicio, MD
|
|
|
|
|
